PMID- 31354492
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 10
DP  - 2019
TI  - Head-to-Head Comparison of the Hypoglycemic Efficacy and Safety Between 
      Dipeptidyl Peptidase-4 Inhibitors and alpha-Glucosidase Inhibitors in Patients With 
      Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
PG  - 777
LID - 10.3389/fphar.2019.00777 [doi]
LID - 777
AB  - Background: The alpha-glucosidase inhibitors (AGIs) are commonly prescribed in Asian 
      patients with type 2 diabetes mellitus (T2DM), but with a high incidence of 
      gastrointestinal side effects. This study was aimed to compare the efficacy and 
      safety of dipeptidyl peptidase-4 (DPP4) inhibitors and AGIs in T2DM patients in a 
      meta-analysis. Methods: Randomized controlled trials were identified via 
      systematic search of PubMed, Embase, and Cochrane's Library databases from 
      inception to February, 2019. Meta-analyses were performed via a random or a fixed 
      effect model according to the heterogeneity. Results: Eighteen studies with a 
      total of 4,051 patients with T2DM were included. The DPP4 inhibitors were 
      associated with lower reduction of glycosylated hemoglobin (HbA1c) as compared 
      with AGIs [weighed mean difference (WMD): -0.37%, p < 0.001]. Subgroup analyses 
      indicated that the benefit of DPP4 inhibitors as compared with AGIs on HbA1c were 
      independent of study design, scale, baseline HbA1c, with or without concurrent 
      medications, or follow-up durations. Moreover, compared to AGIs, DPP4 inhibitors 
      was associated with lower reductions of fasting blood glucose (WMD: -0.53 mmol/L, 
      P < 0.001) and postprandial glucose at 2h (WMD: -0.60 mmol/L, P = 0.04), 
      moderately increased body weight (WMD: 0.34 kg, P = 0.02), and decreased risk of 
      gastrointestinal adverse events [risk ratio (RR): 0.48, P < 0.001], but 
      unaffected risk of symptomatic hypoglycemia (RR: 0.96, P = 0.90). Conclusions: 
      The DPP4 inhibitors are superior to AGIs in T2DM patients for better glycemic 
      control and lower risks of gastrointestinal side effects.
FAU - Li, Zhaoliang
AU  - Li Z
AD  - Department of Endocrinology, the Central Hospital of Tai'an City, Tai'an, China.
FAU - Zhao, Liang
AU  - Zhao L
AD  - Department of Endocrinology, the Central Hospital of Tai'an City, Tai'an, China.
FAU - Yu, Leilei
AU  - Yu L
AD  - Department of Endocrinology, the Central Hospital of Tai'an City, Tai'an, China.
FAU - Yang, Jie
AU  - Yang J
AD  - Department of Endocrinology, the Central Hospital of Tai'an City, Tai'an, China.
LA  - eng
PT  - Systematic Review
DEP - 20190710
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC6635585
OTO - NOTNLM
OT  - dipeptidyl peptidase-4 inhibitors
OT  - meta-analysis
OT  - postprandial glucose
OT  - type 2 diabetes mellitus
OT  - alpha-glucosidase inhibitors
EDAT- 2019/07/30 06:00
MHDA- 2019/07/30 06:01
PMCR- 2019/07/10
CRDT- 2019/07/30 06:00
PHST- 2019/05/05 00:00 [received]
PHST- 2019/06/17 00:00 [accepted]
PHST- 2019/07/30 06:00 [entrez]
PHST- 2019/07/30 06:00 [pubmed]
PHST- 2019/07/30 06:01 [medline]
PHST- 2019/07/10 00:00 [pmc-release]
AID - 10.3389/fphar.2019.00777 [doi]
PST - epublish
SO  - Front Pharmacol. 2019 Jul 10;10:777. doi: 10.3389/fphar.2019.00777. eCollection 
      2019.